Abstract
Colorectal cancer is one of the top contributors to the global burden of cancer incidence and mortality with genetic and environmental factors contributing to its etiology. Modifiable or environmental factors can be the cause of up to 60% of the risk of developing colorectal cancer. Hence, there is a growing interest in specifically defining what can be improved in our lifestyle to reduce this risk, improve the effectiveness of treatments, reduce side effects, and decrease the risk of recurrence. One of the elements directly related to lifestyle is gut microbiota. The microbial ecosystem has a vital role in colorectal cancer prevention and antitumoral response through modulation of the immune system and production of short-chain fatty acids. Numerous approaches have been used to identify healthy microbiota that can reduce the risk of cancer development, improve treatment efficacy, and reduce side effects.
Scientific literature in this subject is growing exponentially and, therefore, systematic reviews and meta-analysis are required to ensure that appropriate recommendations are given to patients.
This work aimed to perform a systematic analysis of the published literature to elucidate whether microbiota modulation through pre-, pro-, symbiotic treatment and/or nutritional intervention can be beneficial for patients diagnosed with colorectal cancer.
Detailed analysis of published studies shows that some prebiotics, such as inulin and resistant starch, probiotics such as lactic strains producers of short-chain fatty acids, and consumption of unprocessed plant products, can be effective recommendations for patients diagnosed with colorectal cancer. This advice should always be individually tailored and followed up by a healthcare professional with expertise in the field.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding was received for completion of this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This is a systematic review.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
There are not restrictions on data availability in this manuscript.
Abbreviations
- CRC
- colorectal cancer
- ROS
- reactive oxygen species
- RNS
- reactive nitrogen species
- MSI
- Microsatellite instability
- SCFA
- Short chain fatty acids
- LPS
- Lipopolysaccharide
- dMMR
- deficient DNA mismatch repair
- AOM
- Azoxymethane
- DSS
- Dextran sodium sulfate
- TNF-α
- tumor necrosis factor alpha
- MPO
- Myeloperoxidase
- PCNA
- Proliferation cellular nuclear antigen
- SLC5A8
- Solute Carrier Family 5 Member 8
- GPR43
- G protein-coupled receptor 43
- CEA
- Carcinoembryonic antigen
- APC
- Adenomatous polyposis coli
- DHM
- 1,2-dimethyl hydrazine
- TGF-β
- Transforming growth factor beta
- TLR2
- toll-like receptor 2
- DC
- dendritic cells
- PD-1
- Programmed cell death protein 1
- PDL-1
- Programmed cell death protein ligand 1
- CTLA-4
- Cytotoxic T-Lymphocyte Associated Protein 4
- CYP
- Cytochrome P450 Family
- GSTM1
- Glutathione S-Transferase Mu 1
- SULT1
- Sulfotransferase Family-1
- PYY
- Peptide tyrosine
- PPARγ
- peroxisome proliferator activated receptor gamma
- 6,BR
- 6-bromoisatin
- NE
- marine extract
- MD
- Mediterranean diet
- LFD
- low fat diet
- HFD
- high fat diet
- EPA
- Eicosapentanoic acid
- PUFA
- polyunsaturated fatty acids
- CRP
- C reactive protein
- SFRP2
- Secreted Frizzled Related Protein 2
- DNMT1
- DNA Methyltransferase 1
- COX-2
- Cyclooxygenase-2
- PGE2
- Prostaglandin E2
- Cxcl
- C-X-C Motif Chemokine Ligand
- Bik
- BCL2 Interacting Killer
- KC
- Keratinocytes-derived chemokine
- Gr-1
- Glucocorticoid Receptor-1
- CTNNB1
- Beta catenin 1
- EGFR
- Epidermal growth factor receptor
- TYMS
- Thymidylate Synthetase
- LPE
- Lisophosphatidiletanolamine
- LPC
- Lisophosphatidylcholine
- G-CSF
- Granulocyte Colony-Stimulating Factor
- GM-CSF
- Granulocyte Macrophage Colony-Stimulating Factor
- HDAC
- Histone Deacetylase
- JAM1
- F11 Receptor
- 5-FU
- 5-florouracil
- EGCG
- epigallocatechin-3-gallate